Galectin Therapeutics Inc.
GALT
Rank in Stocks
#16094
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical... Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC β a joint venture established with SBH Sciences, Inc. β the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Share Price
$3.46
Last synced: 2026-11-09
Market Cap
$227.86M
Change (1 day)
10.19%
Change (1 year)
-40.65%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Galectin Therapeutics Inc. (GALT)
Category
Healthcare
EPS for Galectin Therapeutics Inc. (GALT)
EPS as of June 2026 TTM: $-0.43
According to Galectin Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-0.43. At the end of 2025 the company had an EPS of $-0.48, an increase over its 2024 EPS of $-0.76.
EPS history for Galectin Therapeutics Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.43 | -10.42% |
| 2025 | $-0.48 | -36.84% |
| 2024 | $-0.76 | 2.70% |
| 2023 | $-0.74 | 13.85% |
| 2022 | $-0.65 | 25.00% |
| 2021 | $-0.52 | 26.83% |
| 2020 | $-0.41 | 5.13% |
| 2019 | $-0.39 | 11.43% |
| 2018 | $-0.35 | -23.91% |
| 2017 | $-0.46 | -36.99% |
| 2016 | $-0.73 | -12.05% |
| 2015 | $-0.83 | 15.28% |
| 2014 | $-0.72 | 0.00% |
| 2013 | $-0.72 | 12.50% |
| 2012 | $-0.64 | -29.67% |
| 2011 | $-0.91 | 51.67% |
| 2010 | $-0.60 | -35.48% |
| 2009 | $-0.93 | 132.50% |
| 2008 | $-0.40 | -72.41% |
| 2007 | $-1.45 | 116.42% |
| 2006 | $-0.67 | -53.47% |
| 2005 | $-1.44 | -13.77% |
| 2004 | $-1.67 | 21.90% |
| 2003 | $-1.37 | 1.48% |
| 2002 | $-1.35 | -22.86% |
| 2001 | $-1.75 | 1,798.05% |
| 2000 | $-0.09 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,741.86% |
US
|
|
| $-7.07 | 1,544.19% |
US
|
|
| $-5.29 | 1,130.23% |
AU
|
|
| $12.88 | -3,095.37% |
BE
|
|
| $21.56 | -5,113.95% |
NL
|
Questions about Galectin Therapeutics Inc.'s earnings per share (EPS)
What is Galectin Therapeutics Inc.'s earnings per share (EPS)?
Galectin Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-0.43, as of Jun 2026.
What was Galectin Therapeutics Inc.'s earnings per share (EPS) in 2025?
In 2025, Galectin Therapeutics Inc.'s earnings per share (EPS) was $-0.48, compared with $-0.76 in 2024.
How has Galectin Therapeutics Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Galectin Therapeutics Inc.'s earnings per share (EPS) was highest in 2020 ($-0.41) and lowest in 2024 ($-0.76).
How does Galectin Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?
Galectin Therapeutics Inc.'s earnings per share (EPS) ($-0.43) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.